Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
…
continue reading
In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals. The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992. Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVi ...
…
continue reading
1
Study Supports Osimertinib as Standard of Care for Patients With Locally Advanced EGFR-Mutated NSCLC
8:50
8:50
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
8:50
New data from the Phase III LAURA study, reported in Chicago at the ASCO 2024 Annual Meeting Plenary Session, suggest that the tyrosine kinase inhibitor osimertinib could become standard of care for treating patients whose unresectable locally advanced lung cancers test positive for mutated epidermal growth factor receptor (EGFR) and have no progre…
…
continue reading
1
Study Finds Durvalumab Improved Progression-Free and Overall Survival in Limited Stage Small Cell Lung Cancer
11:34
11:34
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
11:34
FacebookTwitterLinkedinRedditWordFile Edit Insert View Format Table Tools Formats pWords: 89Sample HTMLUndo New page indentation compress encoding option icooption2 option3option4 option5option6 option7option8Clean When the immune checkpoint inhibitor durvalumab was added to standard-of-care chemoradiation treatment for patients with limited-stage …
…
continue reading
1
German Study Finds New Regimen for Hodgkin Lymphoma More Effective, Less Toxic
17:36
17:36
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
17:36
An improvement over standard care in both efficacy and safety of a new combination regimen for treating Hodgkin lymphoma was discussed at the 2024 ASCO Annual Meeting in Chicago. The six-drug BrECADD regimen was compared with the high-achieving German-originated BEACOPP chemotherapy that has been widely adopted as standard of care. During the confe…
…
continue reading
1
Kinase Inhibitor Delivers Synthetic Lethality to Enhance Radiotherapy in Glioblastoma
10:31
10:31
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
10:31
The 2024 AACR Annual Meeting heard that an “efficacy signal” was detected in an international Phase I study of a new radiosensitizer, tested as adjunctive therapy (combined with standard radiation plus temozolomide) in patients with recurrent glioblastoma. After reporting his group’s early findings of AZD1390, an inhibitor of ataxia telangiectasia …
…
continue reading
1
mRNA Vaccine + Checkpoint Inhibitor Combo Had Low Toxicity With Evidence of Efficacy in Advanced NSCLC
8:21
8:21
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
8:21
A combination of a new mRNA vaccine used together with a programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor to treat patients with lung cancer was markedly less toxic than a combination of the same vaccine with chemotherapy. However, it was apparently just effective. This is according to findings from a study reported to the 2024 AACR An…
…
continue reading
1
Earliest Detection of Cancer by Artificial Intelligence Analysis of Circulating Cell-Free DNA Fragmentomes
13:46
13:46
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
13:46
A new blood test that uses artificial intelligence to analyze circulating molecular markers for the earliest signs of ovarian and other cancers has been reported by researchers. At the AACR 2024 Annual Meeting in San Diego, Victor Velculescu, MD, PhD, Co-Director of the Cancer Genetics & Epigenetics Program at Johns Hopkins Kimmel Cancer Center, re…
…
continue reading
1
Clinical Study Shows Selective PARP 1 Inhibitor More Effective, Less Toxic
17:35
17:35
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
17:35
An early study using selective inhibition of the Poly (ADP-ribose) polymerase (PARP) has provided evidence it could bring greater cancer control with less toxicity than the well-proven non-selective PARP 1 and PARP 2 inhibitors already in use for treating a number of tumor types. At the AACR Annual Meeting 2024, Timothy Yap, PhD, MD, MBBS, Vice Pre…
…
continue reading
1
Exercise Deters Prostate Cancer Death & Progression
10:24
10:24
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
10:24
Findings from a new study support a body of evidence showing that physical exercise can bring benefits to patients with advanced prostate cancer. Data from an intervention study reported at the AACR Annual Meeting 2024 are consistent with mounting epidemiological evidence showing that regular physical exercise can help patients with advanced or met…
…
continue reading
1
Bispecific Dual Checkpoint Blockade Extends Life & Slows Progression in Gastric & GE Junction Cancers
9:31
9:31
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:31
Double checkpoint blockade using a single bispecific agent could become the new standard for treating advanced gastric cancer regardless of PD-L1 status, according to research reported at the AACR Annual Meeting 2024. The investigational bispecific antibody drug cadonilimab (used with chemotherapy) significantly extended life and delayed disease pr…
…
continue reading
1
Bispecific T-cell Engager Antibody Brings Deep, Durable Remissions in R/R Multiple Myeloma
15:07
15:07
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
15:07
Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, brought robust clinical benefit to patients with relapsed or refractory multiple myeloma, including those in difficult-to-treat subgroups, in a multi-center, international study reported to the 2024 American Association for Cancer Research Annual Meeting. After…
…
continue reading
1
Exosome-Based Liquid Biopsy Promises Very Early Pancreatic Cancer Detection
12:50
12:50
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
12:50
An opportunity to detect pancreatic cancer at stages where early intervention can greatly extend life and even make cure possible seems to be on offer, according to findings from a study of a new liquid biopsy method based on so-called exosomes: subcellular molecules shed into the circulation by cancer cells. At the AACR Annual Meeting 2024 in San …
…
continue reading
1
Polyepitopic Personalized Vaccine Brought Durable Immune Responses & Clinical Benefit in Resected Head & Neck Cancers
13:00
13:00
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
13:00
Designed with the help of artificial intelligence to recognize multiple genetic features of each patient’s tumor, a small clinical trial of a personalized therapeutic vaccine has shown durable tumor-specific immune responses in patients with surgically resected HPV-negative head and neck squamous cell cancer. The vaccine also prevented relapse in s…
…
continue reading
1
Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery
10:27
10:27
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
10:27
Higher rates of satisfaction and psychosocial well-being and low complication rates were reported by patients who had a new mesh-supported prepectoral method of breast reconstruction using titanized mesh pockets after their surgery for breast cancer. At the 14th European Breast Cancer Conference in Milan, Stefan Paepke, MD, from the Interdisciplina…
…
continue reading
1
Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed
8:38
8:38
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
8:38
The value of adding a radiation boost to postoperative radiotherapy for patients younger than 50 with early breast cancer has been confirmed by 10 years of data from the Young Boost trial conducted in the Netherlands. However, by randomizing patients between the standard radiation boost and a lower dose boost, the study demonstrated comparable effi…
…
continue reading
1
Breast-Conserving Therapy Effective for Ductal Carcinoma in Situ, But Questions Remain
15:40
15:40
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
15:40
A 30-year-long population-based study, reported at the 14th European Breast Cancer conference held in Milan, Italy, showed that breast-conserving therapy for ductal carcinoma in situ (DCIS) had become increasingly effective in preventing the emergence of breast cancer over the long term, but that there were still unanswered questions. The populatio…
…
continue reading
1
Three-Node Breast Cancer Spread: Most Patients Can Safely Avoid Axillary Dissection
9:42
9:42
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:42
Most patients whose breast cancer has spread to more than three lymph nodes can nevertheless be spared extensive axillary dissection, according to the findings of a study presented at the 2024 European Breast Cancer Conference in Amsterdam, The Netherlands. Annemiek van Hemert, a Medical Doctor and PhD candidate at the Surgical Oncology Department …
…
continue reading
1
Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema
34:36
34:36
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
34:36
Artificial intelligence is being harnessed by a team of researchers at Leicester University in the United Kingdom to predict the risk of lymphedema (and potentially other toxicities) from the use of postoperative radiation therapy for breast cancer. The 2024 European Breast Cancer Conference heard the latest news on an artificial intelligence tool …
…
continue reading
1
Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes
8:47
8:47
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
8:47
New data from the Phase III KEYNOTE-756 clinical trial show that adding pembrolizumab immunotherapy to chemotherapy before and after surgery for high-risk breast cancer (which was estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative) resulted in better outcomes for patients regardless of their age or menopaus…
…
continue reading
1
Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer
9:00
9:00
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:00
Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil, MD, in the Department of Radiation Oncology at the Amsterdam UMC in the Netherlands, who reported 5-year results from the ABLATIVE trial to the 14th European Breast Cancer Conference. The researcher…
…
continue reading
1
Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer
9:35
9:35
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:35
Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers. These findings from a study reported at the 14th European Breast Cancer Conference were presented by Heather McArthur, MD, MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical …
…
continue reading
1
Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab
15:44
15:44
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
15:44
About a quarter of all patients with newly diagnosed triple-negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherapy with an agent such as pembrolizumab—even though it improves outcomes among the remaining majority. At the 14th European Breast Cancer Conference, held in Milan, Italy, Laura van ’t Veer, PhD, Progra…
…
continue reading
1
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia
20:15
20:15
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
20:15
An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy. The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are pres…
…
continue reading
1
Important Mantle Cell Lymphoma Findings From the Sympatico Study
13:55
13:55
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
13:55
How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Ander…
…
continue reading
1
World’s Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress
17:44
17:44
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
17:44
2024 is the 20th year of clinical studies conducted as part of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial, a series of investigational approaches to initial therapy for patients with high-risk prostate cancer. Patient accrual has now ended, but practice-changing data continue to eme…
…
continue reading
1
Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression
16:00
16:00
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
16:00
The multicenter RAMOSE randomized clinical trial has found that doublet growth factor tyrosine kinase inhibitor therapy, when compared with standard osimertinib monotherapy, achieved a statistically significant improvement in progression-free survival in patients whose advanced non-small cell lung cancers were driven by mutated epidermal growth fac…
…
continue reading
1
Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias
24:23
24:23
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
24:23
A new targeted drug, revumenib, was found to increase response rates and survival in patients whose previously treated acute leukemias relapsed or were refractory to treatment. A Phase II clinical study found revumenib met its primary endpoint and was stopped early because of a high patient response rate and clinical efficacy. Revumenib acts on the…
…
continue reading
1
INTERLACE Study Boosts Cervical Cancer Survival
18:14
18:14
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
18:14
A marked improvement in the outlook for patients with locally advanced cervical cancer has been achieved thanks to a neoadjuvant regimen using standard anti-cancer drugs added to usual therapy. At the ESMO Congress 2023 held in Madrid, Spain, Mary McCormack, PhD, MBBS, FRCR, Consultant Clinical Oncologist at University College London Hospitals, rep…
…
continue reading
1
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients
18:43
18:43
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
18:43
Patients whose advanced non-small cell lung cancers harbor the RET gene fusion should receive initial treatment with the RET-targeted agent selpercatinib rather than chemotherapy or chemotherapy combined with immunotherapy. This clear message comes from the randomized Phase III LIBRETTO-431 study reported at ESMO Congress 2023 by Herbert Ho Fung Lo…
…
continue reading
1
Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations
8:33
8:33
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
8:33
The preferred first-line treatment for patients with uncommon sensitizing mutations in tumor epidermal growth factor receptor (EGFR) should now be the tyrosine kinase inhibitor (TKI) afatinib, rather than osimertinib, according to Japanese researchers reporting the ACHILLES trial results at the ESMO Congress 2023 held in Madrid. OncTimesTalk corres…
…
continue reading
1
Adjuvant Radiotherapy No Benefit After Radical Prostatectomy
15:24
15:24
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
15:24
Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the ESMO Congress 2023. These results support the use of early salvage radiotherapy…
…
continue reading
1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors Into “Hot” Ones
14:51
14:51
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
14:51
Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin-12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it couldn’t be used because of toxicity. At t…
…
continue reading
1
Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease
15:43
15:43
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
15:43
The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete remission (CR1) has taken a step forward thanks to analysis of the UK NCRI AML17 and AML19 studies, reported at the 65th ASH Annual Meeting and Exposition. Patients who achieved molecular residual disea…
…
continue reading
1
Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma
22:11
22:11
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
22:11
With no standard-of-care treatment for patients with high-risk relapsed/refractory follicular lymphoma, promising remissions have been observed in a Phase II study reported at the 65th ASH Annual Meeting and Exposition. The antibody-drug conjugate loncastuximab tesirine in combination with rituximab brought a very high complete metabolic response r…
…
continue reading
1
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL
12:16
12:16
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
12:16
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.…
…
continue reading
1
Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD
12:32
12:32
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
12:32
In a multinational, Phase III, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In prespecified interim analyses, zanubrutinib was superio…
…
continue reading
1
CLL Frontline Treatment - With Sameer A. Parikh, MBBS, & Alessandra Ferrajoli, MD
14:40
14:40
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
14:40
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.
…
continue reading
1
Sabestomig in Non-Small Cell Lung Cancer: Bi-Specific Antibody Safe and Active
11:10
11:10
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
11:10
Patients with non-small cell lung cancer who have failed initial immunotherapy therapy with anti-programmed cell death ligand-1 (PDL-1) checkpoint inhibitors, have responded to a new “bispecific” antibody that targets both the programmed cell death-1 (PD-1) antibody and also the T-cell immunoglobulin and mucin domain 3 (TIM-3) molecule. Benjamin Be…
…
continue reading
1
Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy
15:23
15:23
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
15:23
Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the 2023 annual congress of the European Society for Medical Oncology (ESMO) held i…
…
continue reading
1
Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition
13:38
13:38
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
13:38
Research presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics found that a combination of two drugs targeting the nRAS mutation had clinical activity in patients with checkpoint-inhibitor refractory melanoma and had potential for treating other solid tumors with mutated nRAS as their oncogenic d…
…
continue reading
1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones
14:50
14:50
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
14:50
Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin 12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it could not be used because of toxicity. At …
…
continue reading
1
Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer
15:22
15:22
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
15:22
Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC internationa…
…
continue reading
1
CLIC Protein Inhibition Key to Metformin’s Anti-Neoplastic Properties
24:17
24:17
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
24:17
The Chloride Intracellular Channel 1 (CLIC1) protein appears to hold the key to understanding the anti-proliferative action of metformin, according to laboratory evidence discussed at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in October 2023, in Boston. At the conference, Michele M. Mazzanti, PhD,…
…
continue reading
1
Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer
18:59
18:59
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
18:59
Dr. Takahashi talks with OncTimes Talk’s Peter Goodwin about the Phase 2 study he presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11 - 15, 2023. Dr. Takahashi reported an improvement in median overall survival among patients with relapsed small cell lung cancer who had the ATR inhibitor…
…
continue reading
1
Mitophagy Discovered as Potential Reason for AML’s Resistance to Venetoclax
15:20
15:20
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
15:20
Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a process in which damaged mitochondria are eliminated to prevent the transmission of death signals, has been identified as a key mechanism that allows leukemia cells to resist the effects of the widely pres…
…
continue reading
1
Unintentional Bias of Breast Cancer Randomized Clinical Trial Interpretations Through Discontinuation Imbalance
11:54
11:54
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
11:54
Some of the big randomized clinical trials could lead to unintentional bias because of an imbalance of assigned treatment discontinuations between experimental and control arms, according to ASCO poster author Faris Tamimi, MD, at the University Health Network Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre. OncTimesT…
…
continue reading
1
Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression
11:43
11:43
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
11:43
Although T-DXd had already been licensed for use in all categories of HER2 positivity, including patients with so-called HER2-low tumors (defined as having immunohistochemical score of 1+ or 2+ with non-amplified in-situ hybridization), doubts have remained about the effectiveness of this antibody drug conjugate in the subset of such patients who a…
…
continue reading
1
Artificial Intelligence Model Predicts Overall Survival in Patients with Metastatic Breast Cancer
9:17
9:17
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:17
A mathematical study of real-world data from 27,855 women whose breast cancer was diagnosed between 2008 and 2020 has shown that a machine-learning artificial intelligence algorithm was able to predict mortality and could become a key weapon in the clinician’s armory when selecting therapies on the basis of predicted survival. Initial findings and …
…
continue reading
1
Axillary Dissection in Older Women With Clinically Node-Negative Breast Cancer
9:17
9:17
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
9:17
Caution was expressed at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting about potential adverse effects from one form of breast cancer treatment de-escalation. A poster warns about risks from omitting axillary sentinel node surgery in older women. In this edition of OncTimesTalk correspondent Peter Goodwin hears about axillary…
…
continue reading
1
Variability of Biological Parameters Between Tumor Biopsy & Surgical Samples in Breast Cancer Patients
8:16
8:16
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
8:16
A real-world study reported at the ESMO Breast Cancer 2023 Annual Congress identified a risk for inappropriate therapeutic decision-making resulting from an alarmingly high rate of false-negative tests coming from biopsy specimens looking for biological parameters such as PR and HER2. Study researchers at the University of Catania suggested tumor h…
…
continue reading
1
Full Compliance With Adjuvant Endocrine Therapy Brings 15 Percent Superior Survival in Patients With Breast Cancer
3:42
3:42
Main Kemudian
Main Kemudian
Senarai
Suka
Disukai
3:42
Patients with breast cancer who complied fully with their adjuvant endocrine medication lived 15 percent longer than those who skipped doses, according to a huge real-world study coordinated from Tübingen University, in Baden-Württemberg, Germany, reported at the 2023 ASCO Annual Meeting. OncTimesTalk correspondent Peter Goodwin discusses the findi…
…
continue reading